Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

dermaPACE® System

The dermaPACE® System utilizes extracorporeal shock wave technology for the treatment of diabetic foot ulcers, eliciting a cellular response in the wound. CPT® codes: 0512T, 0513T.

Visit Product Website

SANUWAVE, Inc.

SANUWAVE, Inc.

SANUWAVE, Inc. is a leader in the development and commercialization of high-energy, focused shock wave technology for the repair and regeneration of conditions of the skin.

800-545-8810
770-419-8634

Portable HV generator/switch with therapy applicator.

• Utilizes high-energy, focused shock waves for wound care
• Non-invasive, short treatment period
• Triggers cellular response for growth factor up-regulation, inflammatory modulation, and angiogenesis/micro-vascularization
• Improves micro-circulation

The dermaPACE® System is US FDA cleared for the treatment of diabetic foot ulcers.
Outside US: acute and chronic conditions of the skin.

Do not treat malignancies, lung and head area, coagulation disorders, children, pregnant patients, wounds greater than 16sq cm, BMI greater than or equal to 40 or patients on dialysis.

Reddening, bruising, tingling, numbness, brief increase of pain is possible, infection (wound), infection beyond the wound.

Store at room temperature.

The dermaPACE® System transfers non-invasive shock wave pulses using therapy applicator into patient using gel as a transmission medium.

Requires 120V AC source

 

Have a product to submit?

Be included in the most comprehensive podiatry products directory and online database.  Learn More

Advertisement